Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 2
1949 3
1950 4
1951 3
1952 2
1953 2
1954 6
1955 2
1956 4
1957 1
1958 7
1959 9
1960 2
1961 2
1962 1
1963 2
1964 9
1966 2
1967 1
1968 1
1969 3
1970 1
1971 2
1972 2
1973 2
1974 1
1975 1
1976 1
1977 1
1978 2
1979 3
1980 1
1981 3
1982 6
1983 2
1984 12
1985 10
1986 7
1987 7
1988 5
1989 13
1990 7
1991 11
1992 7
1993 8
1994 10
1995 10
1996 20
1997 22
1998 16
1999 20
2000 25
2001 32
2002 28
2003 33
2004 36
2005 31
2006 43
2007 55
2008 70
2009 63
2010 69
2011 74
2012 85
2013 87
2014 94
2015 94
2016 85
2017 90
2018 102
2019 85
2020 132
2021 139
2022 131
2023 121
2024 104
2025 97
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,058 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Sezgin Goksu S, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S; ADRIATIC Investigators. Cheng Y, et al. Among authors: navarro a. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. N Engl J Med. 2024. PMID: 39268857 Clinical Trial.
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, Carbone DP, Carlisle JW, Choudhury NJ, Clarke JM, Gadgeel SM, Izumi H, Navarro A, Lau SCM, Lammers PE, Huang S, Hamidi A, Mukherjee S, Owonikoko TK. Sands JM, et al. Among authors: navarro a. Cancer. 2025 Feb 1;131(3):e35738. doi: 10.1002/cncr.35738. Cancer. 2025. PMID: 39876075 Free PMC article. Review.
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohé C, Farago AF, López-Vilariño JA, Cullell-Young M, Nieto A, Vasco N, Gómez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sánchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Dómine M, Paz-Ares L. Aix SP, et al. Among authors: navarro a. Lancet Respir Med. 2023 Jan;11(1):74-86. doi: 10.1016/S2213-2600(22)00309-5. Epub 2022 Oct 14. Lancet Respir Med. 2023. PMID: 36252599 Clinical Trial.
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, Paz-Ares L, Bunn PA; RESILIENT Trial Investigators. Spigel DR, et al. Among authors: navarro a. J Clin Oncol. 2024 Jul 1;42(19):2317-2326. doi: 10.1200/JCO.23.02110. Epub 2024 Apr 22. J Clin Oncol. 2024. PMID: 38648575 Free PMC article. Clinical Trial.
The multiomics blueprint of the individual with the most extreme lifespan.
Santos-Pujol E, Noguera-Castells A, Casado-Pelaez M, García-Prieto CA, Vasallo C, Campillo-Marcos I, Quero-Dotor C, Crespo-García E, Bueno-Costa A, Setién F, Ferrer G, Davalos V, Mereu E, Pluvinet R, Arribas C, Torre C, Villavicencio F, Sumoy L, Granada I, Coles NS, Acha P, Solé F, Mallo M, Mata C, Peregrina S, Gabaldón T, Llirós M, Pujolassos M, Carreras-Torres R, Lluansí A, García-Gil LJ, Aldeguer X, Samino S, Torné P, Ribalta J, Guardiola M, Amigó N, Yanes O, Martínez P, Sánchez-Vázquez R, Blasco MA, Oviedo J, Lemos B, Rius-Bonet J, Torrubiano M, Massip-Salcedo M, Khidir KA, Cao TH, Quinn PA, Jones DJL, Macip S, Brigos-Barril E, Moldes M, Barteri F, Muntané G, Laayouni H, Navarro A, Esteller M. Santos-Pujol E, et al. Among authors: navarro a. Cell Rep Med. 2025 Oct 21;6(10):102368. doi: 10.1016/j.xcrm.2025.102368. Epub 2025 Sep 24. Cell Rep Med. 2025. PMID: 40997805 Free article.
Plasmacytoid dendritic cells control homeostasis of megakaryopoiesis.
Gaertner F, Ishikawa-Ankerhold H, Stutte S, Fu W, Weitz J, Dueck A, Nelakuditi B, Fumagalli V, van den Heuvel D, Belz L, Sobirova G, Zhang Z, Titova A, Navarro AM, Pekayvaz K, Lorenz M, von Baumgarten L, Kranich J, Straub T, Popper B, Zheden V, Kaufmann WA, Guo C, Piontek G, von Stillfried S, Boor P, Colonna M, Clauß S, Schulz C, Brocker T, Walzog B, Scheiermann C, Aird WC, Nerlov C, Stark K, Petzold T, Engelhardt S, Sixt M, Hauschild R, Rudelius M, Oostendorp RAJ, Iannacone M, Heinig M, Massberg S. Gaertner F, et al. Among authors: navarro am. Nature. 2024 Jul;631(8021):645-653. doi: 10.1038/s41586-024-07671-y. Epub 2024 Jul 10. Nature. 2024. PMID: 38987596 Free PMC article.
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, Tam SH, Patil NS, Wen X, Huang M, Hoang T, Meng R, Reck M. Rudin CM, et al. Among authors: navarro a. J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17. J Clin Oncol. 2024. PMID: 37976444 Free PMC article. Clinical Trial.
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman MJ, Dvorkin M, Laktionov K, Navarro A, Juan-Vidal O, Kozlov V, Golden G, Jordan O, Deng CQ, Bentsion D, Chouaid C, Dechev H, Dowlati A, Fernández Núñez N, Ivashchuk O, Kiladze I, Kortua T, Leighl N, Luft A, Makharadze T, Min Y, Quantin X; DISTINCT study investigators. Edelman MJ, et al. Among authors: navarro a. Lung Cancer. 2022 Apr;166:135-142. doi: 10.1016/j.lungcan.2022.03.003. Epub 2022 Mar 4. Lung Cancer. 2022. PMID: 35278766 Clinical Trial.
2,058 results